REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered  Listeria monocytogenes

Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reported Four out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION,

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102  being evaluated   in  ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala  and  Advaxis  stockholders  will  respectively  own  approximately  62 .5% 

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into fiscal third quarter of 2024 MONMOUTH JUNCTION, N.J. , Sept.

Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Presented study design of Phase 1 investigator-sponsor trial with

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it has filed a Certificate of Amendment to the Amended and

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ®  ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) --  Advaxis, Inc. (OTCQX: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it will present data from the Phase 2 study of ADXS-503 in combination

ADXS-PSA in combination with KEYTRUDA ®  in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival  in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases